News

PipelineReview.com4d
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
PARIS, France and TARRYTOWN, NY, USA I April 18, 2025 I The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of ...
PipelineReview.com4d
Akeso’s Ebdarokimab ( IL – 12/IL – 23 Dual – Targeted Monoclonal Antibody) Approved in China for Moderate – to – Severe Plaque Psoriasis
HONG KONG, China I April 18, 2025 I Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is pleased to announce that ebdarokimab, an investigational monoclonal ...
PipelineReview.com7h
Cellenkos’ Off-the-Shelf Treg Cell Therapy Shows Clinical Safety and Preliminary Efficacy in ALS
Cryopreserved allogeneic Treg infusions associated with slowed disease progression and decreased plasma neurofilament level in ALS ...
PipelineReview.com8d
Biocon Biologics Secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
BRIDGEWATER, NJ, USA and BENGALURU, Karnataka, India I April 15, 2025 I Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and ...
PipelineReview.com13d
Outlook Therapeutics® Announces Acceptance of Biologics License Application by U.S. FDA for ONS-5010 as a Treatment for Wet AMD
ISELIN, NJ, USA I April 08, 2025 I Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for ...
PipelineReview.com5d
Endevica Bio Announces First Patient Dosing in Phase 2 Trial in Patients with Stage 4 Metastatic Colorectal Cancer
NORTHBROOK, IL, USA I April 17, 2025 I Endevica Bio, a privately held company developing first-in-class peptide drug candidates, announced today the dose ...
PipelineReview.com6d
Addex Regains Rights to Phase 2 mGlu2 PAM Asset ADX71149
GENEVA, Switzerland I April 17, 2025 I Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of ...
PipelineReview.com8d
Boehringer Ingelheim and Cue Biopharma partner to develop next-generation treatment for autoimmune and inflammatory diseases
INGELHEIM, Germany, and BOSTON, MA, USA I April 14, 2025 I Boehringer Ingelheim and Cue Biopharma, Inc. (Nasdaq: CUE) today announced a strategic research ...
PipelineReview.com7d
IPAX-Linz Study Reports Promising Efficacy for TLX101 Glioma Therapy Candidate
MELBOURNE, Australia and INDIANAPOLIS, IN, USA I April 16, 2025 I Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, Telix, the Company) today announces ...
PipelineReview.com8d
Evommune Initiates Phase 2b Trial of MRGPRX2 Antagonist, EVO756, in Adults with Moderate to Severe Chronic Spontaneous Urticaria
PALO ALTO, CA, USA I April 15, 2025 I Evommune, Inc., a clinical stage biotechnology company discovering and developing new ways to treat immune-mediated ...
PipelineReview.com5d
Magnet-Like Nanoparticle Vaccine Achieves 100% Protection Against H5N1 in Preclinical Trials
BUFFALO, NY, USA I April 17, 2025 I As H5N1 avian influenza continues its spread across species and continents, a vaccine being developed by University of ...
PipelineReview.com6d
Sabin Begins Marburg Vaccine Trial in U.S.
WASHINGTON, DC, USA I April 16, 2025 I The Sabin Vaccine Institute has launched a multi-site Phase 2 clinical trial in the U.S. for its Marburg vaccine ...